Yahoo Finance • last year
Raised $22.9 million of equity capital, paid down $10.0 million of long-term debt Third quarter 2023 total revenue was $8.2 million, down 24% from prior year Expect 2023 revenue at the low end of previously announced guidance range of $37-... Full story
Yahoo Finance • last year
HOLLISTER, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecula... Full story
Yahoo Finance • last year
HOLLISTER, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, a... Full story
Yahoo Finance • last year
HOLLISTER, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecula... Full story
Yahoo Finance • last year
HOLLISTER, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecula... Full story
Yahoo Finance • last year
HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular... Full story
Yahoo Finance • last year
HOLLISTER, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, an... Full story
Yahoo Finance • 2 years ago
First quarter 2023 total revenue was $9.1 million, up 16% sequentially Launch of proprietary AAV-Tek™ Solutions gene therapy product line Company reaffirms 2023 revenue guidance of $42-46 million HOLLISTER, Calif., May 10, 2023 (GLOBE... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, a... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Sartorius BIA Separations, which is part of the international life science group Sartorius, today announced that the companies have... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, an... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, an... Full story
Yahoo Finance • 2 years ago
Third quarter 2022 total revenue was $10.7 million, up 14% year-over-year Company updates 2022 revenue outlook to $40-42 million Cash position of $50 million supports path to profitability HOLLISTER, Calif., Nov. 09, 2022 (GLOBE NEWSWIR... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, research, development, and commercialization of drug therapies, novel vaccine... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and mol... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and mol... Full story
Yahoo Finance • 2 years ago
HOLLISTER, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and mol... Full story